Tipifarnib

Drugbox
IUPAC_name = 6- [amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl] -4-(3-chlorophenyl)-1-methylquinolin-2-one

---

CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 148193
DrugBank =
chemical_formula =
C=27 | H=22 | Cl=2 | N=4 | O=1
molecular_weight = 489.395 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Tipifarnib (Zarnestra) is a drug that is being investigated in patients 65 years of age and older with newly diagnosed acute myeloid leukemia (AML).

The compound was discovered by and is under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C, with registration number R115777.

Approval process

Tipifarnib was submitted to the FDA by Johnson & Johnson for the treatment of AML in patients aged 65 and over with a New Drug Application (NDA) to the Food and Drug Administration (FDA) on January 24, 2005.

In June of 2005, the FDA issued a "not approvable" letter for tipifarnib. [ [http://www.drugs.com/nda/r115777_050630.html R115777 New Drug Application ] ]

References